Jubilant Generics will make the drug available to over 1,000 hospitals providing Covid-19 treatment in India through its distribution network, the company said in a release. Jubilant had entered into a non-exclusive licensing agreement with US Gilead Sciences, Inc. In May, which that granted it the right to register, manufacture and sell Gilead’s investigational drug Remdesivir in 127 countries including India.
